Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 9/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400630 | 0.89 | EPHX2 (0.73) | EPHX2KMT2AMEN1HPGDLMNA | |
| SCHEMBL30089345 | 0.89 | EPHX2 (0.73) | EPHX2KMT2AMEN1HPGDLMNA | |
| SCHEMBL118921 | 0.89 | EPHX2 (0.73) | EPHX2KMT2AMEN1HPGDLMNA | |
| SCHEMBL12235823 | 0.87 | EPHX2 (0.70) | EPHX2KMT2AMEN1HPGDRAB9A | |
| SCHEMBL30877549 | 0.83 | EPHX2 (0.72) | EPHX2KMT2A | |
| SCHEMBL8366872 | 0.83 | EPHX2 (0.75) | EPHX2KMT2AMEN1RAB9A | |
| SCHEMBL16977027 | 0.82 | EPHX2 (0.75) | EPHX2KMT2ALMNA | |
| SCHEMBL694173 | 0.82 | EPHX2 (0.75) | EPHX2KMT2AHPGDLMNA | |
| SCHEMBL4099152 | 0.82 | EPHX2 (0.75) | EPHX2KMT2ALMNA | |
| SCHEMBL1252684 | 0.82 | EPHX2 (0.67) | EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3412279-B1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210008213-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | THE GENERAL HOSPITAL CORPORATION | 2021-01-14 | — | — | US | disclosed |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-9974859-B2 | Nanostructured gels capable of controlled release of entrapped agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012040623-A2 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008213-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | MMP2, CEL, LIPA | EPHX2 231/4885KMT2A 3895/4885MEN1 3515/4885 |
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | EPHX2 231/4885KMT2A 3895/4885MEN1 3515/4885 |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | EPHX2 231/4885KMT2A 3895/4885MEN1 3515/4885 |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | MMP2, MMP1, GUSB | EPHX2 112/4885KMT2A 4034/4885MEN1 3859/4885 |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | EPHX2 231/4885KMT2A 3895/4885MEN1 3515/4885 |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | EPHX2 231/4885KMT2A 3895/4885MEN1 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.